Penka, M <br/><br/>
[The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].  [electronic resource] 

 -  Vnitrni lekarstvi  Jun 2013 
 - 516-31 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0042-773X 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Czech Republic<br/>Female<br/>Fibrinolytic Agents--therapeutic use<br/>Humans<br/>Incidence<br/>Male<br/>Middle Aged<br/>Myeloproliferative Disorders--drug therapy<br/>Quinazolines--therapeutic use<br/>Registries<br/>Thrombocythemia, Essential--drug therapy<br/>Thrombosis--epidemiology